FDA committee recommends approval of Akcea’s FCS drug

This article was originally published here

The US Food and Drug Administration’s (FDA) division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 to support approval of Akcea Therapeutics’ Waylivratm (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply